Add to Basket
|+1 404 474 4654|
|+1 888 205 9894 (TF)|
V-Myc Myelocytomatosis Viral Oncogene Homolog (Avian) (MYC) antibody
|Synonyms||MRTL, c-Myc, bHLHe39, MYC, CMYC, MGC138120, c-myc, C-MYC, LOC100136746|
Chicken, Human, Mouse (Murine), Yeast
Alternatives Immunohistochemistry (Frozen Sections) (IHC (fro)), Chromatin Immunoprecipitation (ChIP), ELISA, Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunoprecipitation (IP), Western Blotting (WB)
|5 references available|
|Quantity||0.1 mL (1.1 mg/ml) (Variants)|
|Price||Product not available in this region.|
|Gene ID||4609, 17869|
|Immunogen||Synthetic peptide: AEEQKLISEEDL conjugated to KLH, corresponding to amino acids408-420 of Human c-Myc.|
|Cross-Reactivity||Chicken, Human, Mouse (Murine)|
|Description||The c-Myc protein is a transcription factor, which is encoded by the c-Myc gene onhuman chromosome 8q24. c-Myc is commonly activated in a variety of tumor cells andplays an important role in cellular proliferation, differentiation, apoptosis and cell cycleprogression. The phosphorylation of c-Myc has been investigated and previous studieshave suggested a functional association between phosphorylation at Thr58/Ser62 byglycogen synthase kinase 3, cyclin dependent kinase, ERK2 and C-Jun N terminalKinase (JNK) in cell proliferation and cell cycle regulation. Studies also have shown thatc-Myc is essential for tumor cell development in vasculogenesis and angiogenesis thatdistribute blood throughout the cells, and which brought extensive attention in thedevelopment of new therapeutic approach for cancer treatment. Alternate Names: anti-c Myc antibody, anti-Cellular myelocytomatosis oncogene antibody, anti-Mycprotein antibody, anti-Myc proto oncogene protein antibody, anti-Myc2 antibody,anti-Niard antibody, anti-Nird antibody, anti-Transcription factor p64 antibody, anti-v mycavian myelocytomatosis viral oncogene homolog antibody, anti-v myc myelocytomatosisviral oncogene homolog (avian) antibody.|
|Specificity||Species Reactivity: Cross-reacts with Human, Mouse and Chicken. Not yet tested in other species. Localization: Nuclear.|
|Application Notes||Suggested working dilutions: chromatin immunoprecipitation 2ul per 0.5 mg of extract,Western Blot 1:500-1:1,000. Positive Controls: HL-60 cells or breast tumors.|
|Buffer||Phosphate buffered saline. Preservative: No Preservative.|
|Storage||Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze thaw cycles.|
|Restrictions||For Research Use only|
Locker, Dowle, Ellis et al.: "c-myc oncogene product expression and prognosis in operable breast cancer." in: British journal of cancer, Vol. 60, Issue 5, pp. 669-72, 1989 (PubMed).
Evan, Lewis, Ramsay et al.: "Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product." in: Molecular and cellular biology, Vol. 5, Issue 12, pp. 3610-6, 1986 (PubMed).
Zhang, Richardson, Roberts et al.: "The Yaf9 component of the SWR1 and NuA4 complexes is required for proper gene expression, histone H4 acetylation, and Htz1 replacement near telomeres." in: Molecular and cellular biology, Vol. 24, Issue 21, pp. 9424-36, 2004 (PubMed).
Robert, Pokholok, Hannett et al.: "Global position and recruitment of HATs and HDACs in the yeast genome." in: Molecular cell, Vol. 16, Issue 2, pp. 199-209, 2004 (PubMed).
Sanders, Gruppuso: "Nucleolar localization of hepatic c-Myc: a potential mechanism for c-Myc regulation." in: Biochimica et biophysica acta, Vol. 1743, Issue 1-2, pp. 141-50, 2005 (PubMed).